 |
 |
 |
 |
 |
Clavulanate |
|||||||
|
Patient No. 1 2 3 Age, yr 44 49 Gender Male Female Male Female Male Male Male Male Male Male Male Female Male Male Male CT Findings 3.5 2.5 cm mass Lobar consolidation 5 3 cm consolidation 5 4 cm consolidation 6 5 cm consolidation Lobar consolidation 4 2.5 cm consolidation 4 2 cm central mass with atelectasis 6 5.5 cm mass 5.5 4.5 cm mass 4 3 cm consolidation 3 cm consolidation 6.5 4.5 cm consolidation 1 cm endobronchial nodule 2 cm nodule Diagnostic Method PTCA or core biopsy Bronchoscopic biopsy PTCA or core biopsy Bronchoscopic biopsy PTCA or core biopsy Bronchoscopic biopsy PTCA or core biopsy Bronchoscopic biopsy Bronchoscopic biopsy PCNA or core biopsy PTCA or core biopsy PTCA or core biopsy PTCA or core biopsy Bronchoscopic biopsy PTCA or core biopsy IV Antibiotics Duration, d * Penicillin G 18 Penicillin G 3 None None None Clindamycin 12 None Ampicillin 2 Clindamycin 3 Penicillin G 3 None Amoxicillin-clavulanate 2 Amoxicillin-clavulanate 2 None None Oral Antibiotics Duration, d Ampicillin 83 Ampicillin 200 Amoxicillin 200 Amoxicillin-clavulanate 412 Amoxicillin 90 Clindamycin 76 Amoxicillin-clavulanate 223 Amoxicillin-clavulanate 147 Clindamycin 365 Amoxicillin-clavulanate 167 Amoxicillin-clavulanate 150 Amoxicillin 167 Amoxicillin-clavulanate 215 Amoxicillin-clavulanate 142 Amoxicillin-clavulanate 158.
Table 1. Studies involving serotonin antagonists to treat akathisia Reference Poyurovsky & Weizman 1997 ; Poyurovsky et al 1998 ; Poyurovsky et al 1999 ; No. of patients Drug and dose 8 16 15 Mianserin 15-30 mg daily Mianserin 15 mg daily Placebo Mianserin 15 mg daily Ritanserin 30-40 mg daily Trial design Open label comparison Open label Double-blind placebo-controlled Open label Rating scale BARS BARS BARS Outcome Significant reduction in BARS1 BARS decreased from 2.88 to 1.00 BARS decreased from 3.2 to 1.53 Akathisia score decreased from 1.3 to 0.4 HAS decreased from 16.4 to 7.4 BARS decreased from 4 to 0.94, because amoxicillin and clavulanate potassium tablets.
Ceftriaxone levels in the CNS were similar in patients who received dexamethasone compared to those who did not AC Buke et al, Int J Antimicrob Agents 2003; 21: 452 ; . A study in animals found that dexamethasone decreases vancomycin levels in the CSF when used alone, but not when vancomycin is combined with rifampin J Martinez-LaCasa et al, J Antimicrob Chemother 2002; 49: 507 ; . PNEUMONIA The "atypical" pathogens Mycoplasma pneumoniae and Chlamydophilia pneumoniae formerly Chlamydia pneumoniae ; probably cause most cases of community-acquired bacterial pneumonia. Legionella, another atypical organism, is less common. Among hospitalized patients with community-acquired bacterial pneumonia, S. pneumoniae probably is the most common pathogen. Other bacterial pathogens include H. influenzae, Klebsiella pneumoniae, and occasionally other gram-negative bacilli and anaerobic mouth organisms. Hospital-acquired nosocomial ; pneumonia is often caused by gram-negative bacilli, especially P. aeruginosa, Klebsiella spp., Enterobacter spp., Serratia spp., and Acinetobacter spp.; it can also be caused by S. aureus. Guidelines for the treatment of pneumonia have recently been published Treatment Guidelines 2003; 1: 83; LA Mandell et al, Clin Infect Dis 2003; 37: 1405 ; . In ambulatory patients, an oral macrolide erythromycin, azithromycin or clarithromycin ; , doxycycline, or a fluoroquinolone with good anti-pneumococcal activity such as levofloxacin, gatifloxacin or moxifloxacin is generally used for otherwise healthy adults. Pneumococci may, however, be resistant to macrolides JR Lonks et al, J Antimicrob Chemother 2002; 50 suppl 2: 87 ; and to doxycycline, especially if they are resistant to penicillin. For older patients or those with co-morbid illness, a fluoroquinolone may be a better choice. Fluoroquinolone-resistant pneumococci have also been described rarely MR Jacobs et al, J Antimicrob Chemother 2003; 52: 229 ; . In community-acquired pneumonia requiring hospitalization, ceftriaxone or cefotaxime, plus a macrolide erythromycin, azithromycin or clarithromycin ; is recommended pending culture results RB Brown et al, Chest 2003; 123: 1503 ; . Alternatively, a fluoroquinolone with good activity against S. pneumoniae levofloxacin, gatifloxacin or moxifloxacin ; can be substituted. If aspiration pneumonia is suspected, metronidazole or clindamycin can be added. Moxifloxacin, which has anaerobic activity, is a reasonable alternative. In treating pneumococcal pneumonia due to strains with intermediate degrees of penicillin resistance minimal inhibitory concentration [MIC] 2 g mL ; , ceftriaxone, cefotaxime, or high doses of either IV penicillin 12 million units daily for adults ; or oral amoxicillin can be used. For highly resistant strains MIC 2 g mL ; , fluoroquinolone levofloxacin, gatifloxacin or moxifloxacin ; , vancomycin or linezolid may be required, and should be added in severely ill patients such as those requiring admission to an ICU ; and those not responding to a -lactam. For initial treatment of hospital-acquired pneumonia, in which antimicrobial resistance is frequent and can emerge during treatment, Medical Letter consultants would use piperacillin tazobactam, ticarcillin clavulanate or a carbapenem imipenem or meropenem ; , all of which have broad gram-positive, gram-negative and anaerobic activity, or cefepime, which has broader activity than ceftriaxone or cefotaxime against gramnegative organisms. In severely ill patients, an aminoglycoside tobramycin, gentamicin or amikacin ; or ciprofloxacin should be added to improve Pseudomonas coverage. Addition of vancomycin or linezolid should be considered in hospitals where MRSA is common. INFECTIONS OF THE GENITOURINARY TRACT URINARY TRACT INFECTION -- Acute uncomplicated cystitis in women can be effectively and inexpensively treated, before the infecting organism is known, with a three-day course of oral trimethoprimsulfamethoxazole. In areas where the prevalence of E. coli resistant to trimethoprim-sulfamethoxazole exceeds 15% to 20%, a fluoroquinolone can be substituted K Gupta et al, Ann Intern Med 2001; 135: 41 ; . Other alternatives include 5- to 7-day regimens of nitrofurantoin, or a single dose of fosfomycin TM Hooton, Int J Antimicrob Agents 2003; 22: S65; SD Fihn, N Engl J Med 2003; 349: 259 ; . Based on the results of susceptibility testing, nitrofurantoin, amoxicillin or a cephalosporin can be used to treat urinary tract infections in pregnant women LE Nicolle, Int J Antimicrob Agents 2003; 22: 1 nitrofurantoin should not be given near term or during labor or delivery because it can cause hemolytic anemia in the newborn. Acute uncomplicated pyelonephritis can often be managed with a 7-day course of an oral fluoroquinolone. Urinary tract infections that recur after use of antimicrobial agents or are acquired in hospitals or nursing homes are more likely to be due to antibiotic-resistant gram-negative bacilli, S. aureus or enterococci. A fluoroquinolone, oral amoxicillin clavulanate or an oral. GR HU IE 2004 036713 02.11.2004 WO 2005 041929 2005 US 700838 PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT SYNCHRONISIERTER FREISETZUNG VON SOLUBILISATOREN PHARMACEUTICAL COMPOSITIONS WITH SYNCHRONIZED SOLUBILIZER RELEASE COMPOSITIONS PHARMACEUTIQUES LIB RATION SYNCHRONIS E DE SOLUBILISANT Lipocine, Inc., 675 Arapeen Drive, Suite 202, Salt Lake City, UT 84108, US FIKSTAD, David, T., Salt Lake City, UT 84102, US VENKATESHWARAN, Srinivasan, Salt Lake City, UT 84124, US GILIYAR, Chandrashekar, Salt Lake City, UT 84102, US CHEN, Feng-Jing, Salt Lake City, UT 84111, US PATEL, Mahesh, V., Salt Lake City, UT 84124, US, because amoxillin clavulanate. Lanate 710 days ; , and azithromycin 5 days ; versus amoxicillin clavulanate 710 days ; . Analysis of 3 studies47, 51, 67 comparing ceftriaxone with amoxicillin showed no difference in 5- to 10-day clinical failure. Clavulanate potClinical studies in pediatric patients aged 2 months to 12 years ; , one canadian clinical trial was conducted which compared amoxicillin and clavulanate potassium for oral suspension and chewable tablets 45 4 mg kg day divided q12h ; for 10 days versus amoxicillin and clavulanate potassium for oral suspension and chewable tablets 40 10 mg kg day divided q8h ; for 10 days in the treatment of acute otitis media and anastrozole. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No: 552 Title: A two-part crossover study to assess the pharmacokinetics of amoxicillin after administration with clavulanate of pharmacokinetically enhanced formulations of amoxicillin in healthy volunteers. Rationale: In this study, the pharmacokinetic and pharmacodynamic profile of amoxicillin and clavulanate in five novel pharmacokinetically enhanced PE ; formulations were compared in order to select a formulation for further development. The aim of this new formulation was to provide more effective therapy against drug-resistant pathogens by increasing the plasma concentration of amoxicillin and clavulanate over a longer period of time to ensure susceptibility for S. pneumoniae close to 100%. Phase: I Study Period: 7 June 1999 to 7 July 1999. Study Design: Open-label, randomized, two-part crossover design. Randomization was stratified by gender. Centres: Single centre Germany ; . Indication: None. Treatment: Each subject participated in two dosing sessions, separated by at least three days. Each subject received a single dose of the reference formulation and was randomly assigned to receive a single dose of one novel formulation: Formulation A: PE amoxicillin trihydrate 875mg, formulated to release over 4 hours approximately 4% xanthan gum ; , co-administered with an amoxicillin clavulanate 875 125mg tablet. Formulation B: PE amoxicillin trihydrate 875mg, formulated to release over 1 hour approximately 0.5% xanthan gum ; , co-administered with an amoxicillin clavulanate 875 125mg tablet. Formulation C: PE crystalline sodium amoxicillin 875mg, formulated to release over 4 hours approximately 4% xanthan gum ; , co-administered with an amoxicillin clavulanate 875 125mg tablet. Formulation D: PE crystalline sodium amoxicillin 875mg, formulated to release over 1 hour approximately 2% xanthan gum, 156mg Citric acid ; , co-administered with an amoxicillin clavulanate 875 125mg tablet. Formulation E: PE crystalline sodium amoxicillin 500mg, formulated to release over 4 hours approximately 4% xanthan gum ; , co-administered with an amoxicillin clavulanate 500 125mg tablet and a trihydrate amoxicillin 500mg tablet. Formulation F, Reference: One tablet of trihydrate amoxicillin 875mg and an amoxicillin clavulanate 875 125mg tablet. Objectives: To assess amoxicillin pharmacokinetics of PE formulations of amoxicillin when co-administered orally with an amoxicillin clavulanate tablet, in healthy male and female volunteers; to determine the combination which best meets the acceptance criteria for use in phase III clinical trials. The target PK values proposed included a mean time above the minimum inhibitory concentration T MIC ; of amoxicillin at MIC of 4g mL least 40% of the 12-hour dosing interval i.e. to be at least 4.8 hours ; and a mean maximum plasma concentration Cmax ; to be equal to or greater than 16g mL 4 times MIC of 4g mL ; Statistical Methods: Subjects were included in the pharmacokinetic analysis if they had evaluable data from both the novel and reference formulations. All subjects who received at least one dose of study medication were included in the evaluation of safety. Loge-transformed Cmax and untransformed T MIC for each of the novel formulations were analysed using analysis of covariance ANCOVA ; fitting a single term for formulation and fitting the data from the reference formulation as a covariate. The 95% confidence intervals CIs ; for the means of each formulation were constructed using the residual variance from the model. For Cmax, the CI estimates on the log scale were then back-transformed to obtain the 95% Cis of the geometric mean. Study Population: Healthy male or female subjects, aged between 18-60 years, inclusive, who passed a comprehensive medical interview and were not allergic to penicillin antibiotics. Key exclusion criteria included use of any prescription or non-prescription medication, pregnancy, and positive hepatitis tests. Adequate contraceptive measures were required for females of child-bearing potential. Number of Subjects: All Subjects Planned, N 40 Dosed, N 40 Completed, n % ; 40 100 ; Total Number Subjects Withdrawn, n % ; 0 Withdrawn due to Adverse Events, n % ; 0. Regarding future plans, infrastructure, equipment and personnel required was presented by Dr. P. Rajagopal, Prof. & Head and Dr. Dharma Rakshak, Prof. & Unit Head to team of officers appointed by the Central Government to study the application of NIMS for upgradation to the level of All India Institute of Medical Sciences has visited NIMS on January 5, 2004 and arava. 28. Madsen, L., R. K. Petersen, M. B. Srensen, C. Jrgensen, P. Hallenborg, L. Pridal, J. Fleckner, E-Z. Amri, P. Krieg, G. Furstenberger, R. K. Berge, and K. Kristiansen. 2003. Adipocyte differentiation of 3T3-L1 preadipocytes is dependent on lipoxygenase activity during the initial stages of the differentiation process. Submitted 29. Hansen, J. B., R. K. Petersen, B. Larsen, J. Bartkova, J. Alsner, and K. Kristiansen. 1999. Activation of peroxisome proliferator-activated receptor gamma bypasses the function of the retinoblastoma protein in adipocyte differentiation. J. Biol. Chem. 274: 2386-2393. 30. Folch, J., M. Lees, and G. H. Sloane-Stanley. 1957. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 226: 497-509. 31. Tronstad, K. J., K. Berge, E. Dyry, L. Madsen, and R. K. Berge. 2001. Growth reduction in glioma cells after treatment with tetradecylthioacetic acid: changes in fatty acid metabolism and oxidative status. Biochem. Pharmacol. 61: 639-649.
Conclusion : the new etest esbl strip containing cefepime– clavulanate is a valuable supplement to current methods for detection of esbls. Clavulanate and tetracycline was evaluated by Etest on 38 isolates. For all strains tested, the minimum inhibitory concentration values obtained were low and substantially below effective serum concentrations for these antibiotics.These data enable us to devise suitable treatments for acute development of apical lesions and to prevent dissemination of this source of infection to the rest of the host. Le Gonidec P. et al. [Impact of hospital infection on medical expenditures in a continuing care and rehabilitation service at a geriatric hospital]. Pathol Biol Paris ; . 1998; 46 6 ; : 398-402.p Abstract: The costs of medical expenditures such as drugs, medical devices MD ; , biological assays and nurses workload, were measured, before and after the onset of nosocomial infection NI ; , in rehabilitation care departments of a 1000-beds geriatric teaching hospital. Data were collected retrospectively in medical records and nursing records. Nurse's workload was measured by the French indicator "Soins Infirmiers Personnalise a la Personne Soignee" SIIPS ; . A week before and a week after the diagnosis of hospital-acquired infection, medical consumptions were compared. During the study 38 of the 206 patients admitted in rehabilitation care wards presented hospital-acquired infection. Data were collected for 31 of these 38 patients. Nosocomial infections are associated with an increased pharmaceutical dispensing: medication mainly antibiotics ; and medical device's cost; and an increased nurse's workload.This study suggests that infection surveillance may be helpful to a better understanding of pharmaceutical dispensing variation in geriatric rehabilitation care departments. Le Moing V et al. Use of corticosteroids in glomerulonephritis related to infec. tive endocarditis: three cases and review. Clin Infect Dis. 1999; 28 5 ; : 1057-61.p Abstract: We report the cases of three patients treated for infective endocarditis IE ; for whom corticosteroids were added to the antibiotic treatment.They all had clinical and biological evidence of immune-mediated glomerulonephritis. The microorganisms responsible for IE were Coxiella burnetii, Streptococcus bovis, and Cardiobacterium hominis. Median duration of IE before antimicrobial therapy was 7 months. In all patients, renal function deteriorated despite appropriate antimicrobial treatment for a mean duration of 16 days, but it improved after addition of corticosteroid therapy. All patients were cured of IE. A literature review revealed four additional cases of IE-related glomerulonephritis in which adjunctive immunosuppressive therapy was considered to be effective. Although corticosteroid therapy is generally not recommended for IE, it should be considered for patients whose renal dysfunction secondary to glomerulonephritis does not improve with appropriate antimicrobial treatment, especially if the duration of the illness is long. Le Saux N. et al. Antimicrobial use in febrile children diagnosed with respiratory tract illness in an emergency department. Pediatr Infect Dis J. 1999; 18 12 ; : 1078-80.p Abstract: BACKGROUND: In an era of increasing antibiotic resistance, the prevalence of antibiotic usage and associated factors should be ascertained to optimize their use.We set out to determine the prevalence of antibiotic use in febrile children diagnosed with respiratory tract illnesses at a children's hospital emergency department; to determine how often viral studies were conducted; and to identify patient characteristics associated with antibiotic use. METHODS: We conducted a retrospective study of antibiotic use in febrile children 3 months to 10 years old presenting with respiratory illnesses during two 1-month periods. Patient charts and laboratory tests were reviewed. Antibiotic use was related to diagnosis by logistic regression. RESULTS: A total of 836 patient visits were selected. Antibiotics were prescribed for otitis media in 96% of patients, for pneumonia in 100%, for pharyngitis in 66%, for bronchiolitis in 38%, for reactive airway disease in 24% and for viral or "upper respiratory tract illness" in 14%. For viral illness or upper respiratory tract infection, antibiotic use was associated with a fever duration of 48 h [odds ratio OR ; , 3.2; 95% confidence interval CI ; 1.7, 5.9] and having a chest radiograph performed OR 2.1; 95% CI 1.02, 4.37 ; . Patients with pharyngitis who had a throat swab and azulfidine and clavulanate.
A new package should be started on the eighth day after the last tablet was taken. Clavulanate pregnancy
|